<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847222</url>
  </required_header>
  <id_info>
    <org_study_id>SGHV-005</org_study_id>
    <nct_id>NCT01847222</nct_id>
  </id_info>
  <brief_title>An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.</brief_title>
  <official_title>An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prolong Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prolong Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety assessment of SANGUINATE™ in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety and Pharmacokinetic assessment in ascending doses of SANGUINATE™ in Healthy
      Volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to completion of competing study.
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>7 days</time_frame>
    <description>Adverse events of SANGUINATE™</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Drug Safety</condition>
  <arm_group>
    <arm_group_label>SANGUINATE™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-bHb-CO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SANGUINATE™</intervention_name>
    <description>PEG-bHb-CO</description>
    <arm_group_label>SANGUINATE™</arm_group_label>
    <other_name>PEG-bHb-CO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Normal Saline Solution</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male Volunteers;

          -  Age ≥18 years and ≤45 years;

          -  BMI ≥20- ≤30 kg/m²

          -  No clinically significant screening observations

        Exclusion Criteria:

          -  Female volunteers;

          -  Any history of significant cardiac, renal, neurologic, metabolic, pulmonary,
             gastrointestinal, chronic hepatic disease or any other disease which in the judgment
             of the Investigator would interfere with the study or confound the results;

          -  History of allergy or major allergic reactions considered to be clinically significant
             by the Investigator;

          -  Any screening assessment determined to be clinically significant by the Investigator;

          -  Donate blood within 60 days of screening or otherwise experienced blood loss &gt;250 mL
             within the same period;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Brenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Facility</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Care Facility</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <last_update_submitted>January 5, 2015</last_update_submitted>
  <last_update_submitted_qc>January 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

